Skin Study

RCS-01: Sun-damaged and Aging Skin

In 2017, RepliCel completed a phase 1 human clinical trial of RCS-01 in patients with aging or sun-damaged skin. The study’s results supported the product’s safety and provided encouraging indications of its potential efficacy in terms of impacting what we call ‘biomarkers’ in the layer under the skin which keeps it looking young and healthy.

In the study, injection of RCS-01 was associated with changes in biomarkers and in levels of type 1 collagen, elastin and other extracellular dermal matrix components found in youthful skin.

RepliCel continues to advance its cell therapy and dermal injection programs through ongoing research and development.

Peer-reviewed Papers

RCS-01 for Aging and Sun-damaged Skin

Autologous Cell Therapy for Aged Human Skin: A Randomized, Placebo-Controlled, Phase-I Study